Posts

Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China